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ABSTRACT 
 
 
The Micronutrient Profile of the Typical American Diet Enhances  
 
Colorectal Carcinogenesis  
 
 
by 
 
 
Stephany Perez Monsanto, Master of Science 
 
Utah State University, 2013 
 
 
Major Professor:  Dr. Abby D. Benninghoff 
Department:  Animal, Dairy and Veterinary Sciences 
 
 
The typical Western dietary pattern is characterized by the consumption of 
energy-dense, nutrient-poor foods and has been linked to increased risk of colorectal 
cancer (CRC). Our research group previously developed the total Western diet (TWD) 
that emulates typical human dietary intakes of macro- (carbohydrates, proteins, and fats) 
and micronutrients (vitamins and minerals) on an energy density basis for rodents. In the 
present study, we sought to determine the impact of TWD on biomarkers of metabolic 
syndrome and obesity in comparison to a commercial 45% fat diet used for models of 
diet-induced obesity (DIO diet) and the standard basal AIN93G diet, which is optimized 
for rodent health. Also, we included 2 additional test diets to evaluate the contribution of 
the micronutrient (vitamin- and mineral-modified diet, [VMM]) or macronutrient (macro-
modified diet [MM]) contents of the TWD in development of cancer, obesity, and 
glucose intolerance. A chemical carcinogenesis model of inflammation-associated colon 
cancer was employed to evaluate impact of diets on colon cancer in mice. As expected, 
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mice consuming the DIO diet acquired an obesity/metabolic syndrome phenotype 
typified by increased food energy intake, greater rate of body weight gain, increased 
proportion of body composition as fat mass, higher fasting glucose, impaired glucose 
tolerance, and higher circulating levels of leptin. However, consumption of TWD did not 
alter any of these classic biomarkers of metabolic health, as these mice adjusted food 
intake so that energy consumption was similar to that for mice fed AIN93G. A different 
pattern was observed for colon carcinogenesis. Consumption of the TWD or VMM diet 
markedly increased colon tumor multiplicity and size compared to the AIN93G control, 
whereas consumption of the DIO or MM diets did not enhance colon tumorigenesis. 
Collectively, these observations point to a critical role of dietary micronutrients in colon 
carcinogenesis, and that this promoting effect is likely unrelated to the metabolic 
syndrome phenotype induced by a high fat diet. Moreover, our observations emphasize 
the need to take into account the micronutrient content of rodent basal diets when 
modeling typical U.S. nutrition in pre-clinical animal experiments in order to improve the 
translation of these studies to human nutrition and dietary intervention programs. 
(93 pages)  
  
  
v 
PUBLIC ABSTRACT 
 
 
The Micronutrient Profile of the Typical American Diet Enhances  
 
Colorectal Carcinogenesis  
 
 
by 
 
 
Stephany Perez Monsanto, Master of Science 
 
Utah State University, 2013 
 
 
 The typical Western dietary pattern is characterized by the consumption of high-
energy foods that are low in essential nutrients and has been linked to increased risk of 
colorectal cancer (CRC). Our research group previously developed the total Western diet 
(TWD) to emulate typical human dietary intakes of macro- (carbohydrates, proteins, and 
fats) and micronutrients (vitamins and minerals) based on food energy basis for rodents. 
In the present study, we sought to determine the impact of TWD on indicators of 
metabolic syndrome and obesity in comparison to a commercial 45% fat diet used for 
models of diet-induced obesity (DIO diet) and the standard basal AIN93G diet, which is 
optimized for rodent health. Also, we included 2 additional test diets to evaluate the 
contribution of the micronutrient (vitamin- and mineral-modified diet, [VMM]) or 
macronutrient (macro-modified diet [MM]) contents of the TWD in development of 
cancer, obesity, and glucose intolerance. We employed a chemical carcinogen model of 
colon cancer in mice with an agent to induce inflammation of the gastrointestinal tract to 
evaluate the impact of these experimental diets on formation of colon tumors. As 
expected, mice consuming the DIO diet gained excess weight and had symptoms typical 
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of metabolic syndrome, including greater rate of body weight gain, increased proportion 
of body fat mass, higher levels of blood glucose, impaired glucose tolerance, and higher 
circulating levels of the hormone leptin. However, consumption of TWD did not alter any 
of these biomarkers of metabolic health, as these mice adjusted food intake so that energy 
consumption was similar to that for mice fed AIN93G. Conversely, consumption of the 
TWD or VMM diet markedly increased colon tumor number and size compared to the 
AIN93G control, whereas consumption of the DIO or MM diets did not enhance colon 
tumor formation. Collectively, these observations point to a critical role of micronutrients 
in the development of colon cancer, and that this promoting effect is likely unrelated to 
the metabolic syndrome symptoms acquired by mice consuming strictly a high fat diet. 
Moreover, our observations emphasize the need to take into account the micronutrient 
content of rodent basal diets when modeling typical U.S. nutrition in pre-clinical animal 
experiments in order to improve the translation of these studies to human nutrition and 
dietary intervention programs. 
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 INTRODUCTION 
 
 
Colorectal cancer is the third leading cause of cancer death and the third most 
commonly diagnosed cancer in men and women in the United States (1). In the last 
twenty years, global incidence rates of colorectal cancer have been increasing, reportedly 
due to an increase in the prevalence of certain cancer-associated practices, such as 
decreased physical activity and “westernized” diets (2). The typical Western Diet is a 
dietary trend characterized by increased consumption of highly processed foods that 
contain excess levels of fat, sodium, and refined sugars and are generally low in essential 
vitamins, minerals, and fiber (3-5). This dietary pattern is believed to play a critical role 
in the development of several chronic conditions that have increased in prevalence over 
the last 50 years, including obesity, type II diabetes, metabolic syndrome (5, 6) as well as 
colorectal cancer (7-9). Because of the increasing socioeconomic burden of colorectal 
cancer, a large body of research has been dedicated to the study of the role of nutrition on 
the development of this and other related conditions with the purpose of elucidating the 
mechanisms behind their pathology. 
 
Statistics on colorectal cancer 
Colorectal cancer (CRC) is the fourth most common cause of death worldwide, 
with approximately 608,000 deaths occurring each year (10). Global incidences of CRC 
have increased over the last twenty years, and this disease is more prevalent in 
economically developed countries, which account for up to 60% of reported cases (2, 10). 
The lifetime risk of developing CRC in the U.S. is about 5%, and the risk is slightly 
lower in women than in men. Based on the level of economic development of the region, 
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Central and Eastern Europe are estimated to have the highest mortality rates in both sexes 
(20.1 for male, 12.2 for female per 100,000), while Middle Africa is estimated to have the 
lowest mortality rate (3.5 for male, 2.7 for female). In the United States, significant 
improvements in colorectal screening and treatment methods have caused mortality rates 
to decrease 2.8% per year in men and 2.6% per year in women since 1998. However, 
according to data collected between 1975 and 2007 from the Surveillance, Epidemiology, 
and End Results (SEER) Program, colorectal cancer incidence rates have declined in the 
U.S. among adults 50 years and older, but have increased among adults younger than 50 
years (1). Although the precise cause for this trend remains a topic of debate, current data 
point to several environmental factors as potential contributors to these apparent shifts in 
cancer risk. 
 
Risk factors for colorectal cancer 
 CRC risk is influenced by external modifiable factors (lifestyle and diet) and 
intrinsic non-modifiable factors (genetic predisposition). Heredity accounts for 
approximately 30% of all the diagnosed cases of CRC, of which 5% are attributed to 
well-characterized heritable genetic defects (11, 12). The remaining cases are generally 
attributed to either single-gene mutations that are less pervasive than those observed in 
well-characterized syndromes, or mutations on multiple susceptibility loci that result in 
additive effects. However, several hereditary syndromes are well described and have 
been strongly linked with CRC development. 
Lynch Syndrome (or hereditary nonpolyposis colorectal cancer) is an autosomal 
dominant cancer-susceptibility disorder caused primarily by germline mutations of 
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mismatch repair genes. Although it predisposes subjects to several other types of cancers, 
it accounts for about 3% of CRC cases and can increase CRC risk as much as 80% 
depending on the type of mutation (11, 13).  
Familial adenomatous polyposis (FAP) is one of the best-studied polyp-forming 
syndromes, although it accounts for less than 1% of CRC cases (11, 14). FAP is an 
autosomal dominant disease that results from germline mutations in the APC gene. The 
severity of the condition varies depending on the location of the mutation within the APC 
gene, which produces other variants of the condition (i.e. Attenuated FAP, Gardner 
syndrome, and Turcot syndrome).  
MUTYH-associated polyposis (MAP) is a germline inactivation of the base 
excision repair gene MUTYH (or MYH), which causes adenomatous polyposis of the 
colorectum and an increased risk of CRC. In patients carrying this mutation, the risk of 
CRC is nearly 100% by 60 years of age (11, 15).  
Hamartomatous polyposis syndromes are a group of inherited conditions that 
exhibit varying individual characteristics, but commonly show hamartomatous rather than 
epithelial polyp histology. Disease-associated mutations occur in different genes, some of 
which are STK11, SMAD4, and BMPR1A. Individuals with any of the related conditions 
have an increased risk for several types of cancer, including CRC. These syndromes 
account for less than 1% of CRC cases (11, 16). 
Familial non-syndromic colorectal cancer refers to any CRC cases involving an 
uncommon genetic defect that is sufficiently penetrant to give rise to an autosomal-
dominant segregation pattern. Thus, specific genetic markers for these cases are not 
available. Risk of CRC is approximately 2- to 3-fold greater for an individual with a first-
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degree relative that has been diagnosed with CRC after age 50. The disease can be caused 
by genetic polymorphisms, allelic variants, chromosomal instability, aberrant DNA 
methylation, and other environmental factors (11, 15, 17). 
Finally, another critical non-modifiable risk factor for CRC is individual medical 
history. Individuals who have been previously diagnosed with CRC (even if they have 
recovered), who have had one or more adenomatous polyps, who suffer from 
inflammatory conditions (e.g. Crohn’s disease, ulcerative colitis, and inflammatory bowel 
disease), or who suffer from a condition strongly associated with CRC (e.g. Type II 
diabetes or obesity), have an increased risk of developing CRC (1, 18). Additional 
conditions that have been strongly associated with an increased risk of CRC include 
obesity (9, 19, 20), metabolic syndrome (8, 21, 22), diabetes (23-25), and nonalcoholic 
fatty liver disease (7, 26, 27). 
 Lifestyle and diet are external modifiable factors that greatly influence CRC risk 
and disease progression, and global patterns of CRC incidence closely align with patterns 
of physical activity and dietary trends. High levels of physical activity have been 
associated with lower CRC risk and lower mortality (1, 28, 29), even after CRC diagnosis 
(30). Data for 2005 from the Centers for Disease Control and Prevention (CDC) show 
that more than half of U.S. adults fail to meet the amounts of physical activity 
recommended by the CDC and the American College of Sports Medicine (31), a figure 
that correlates with the high rates of CRC reported in the U.S. 
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Animal models of colorectal carcinogenesis 
In general, most pre-clinical studies of CRC employ a either a chemical 
carcinogenesis animal model, in which the hydrazine compounds 1,2-dimethylhydrazine 
(DMH) or its metabolite azoxymethane (AOM) are used to induce sporadic tumors in the 
colon, or a transgenic animal model, wherein mice carry a heterozygous mutation in the 
adenomatous polyposis coli (APC) gene leading to development of tumors in the small 
intestine and colon (see 32 for a comprehensive review). The most widely used 
transgenic model of intestinal and colon cancer is the APC
Min/+
 mouse (33). The APC 
gene regulates various cellular pathways, including Wnt-signaling (involved in cell 
proliferation), cell-cell adhesion, cell cycle progression, and apoptosis. When one or 
several of these pathways are disrupted via mutation, the cell could escape normal 
constraints on cell proliferation and acquire a survival advantage. For this reason, a 
mutation in the APC gene is considered one of the most important initiating events in 
sporadic CRC (34). The defining feature of this cancer model is a nonsense mutation that 
results in a truncated APC protein at amino acid 850, which induces the formation of 
polyps in the mouse intestine. The majority of these polyps develop in the small intestine, 
which is why this model is deemed more useful for the study of hereditary colon cancer 
types, such as FAP. However, others have developed modifications of this transgene to 
improve the cancer model so that it more closely emulates human CRC, including a) 
modifiers of Min (Mom), which comprise several loci located on different chromosomes 
which have an effect of tumor development (e.g. mom1, mom2); b) Apc variations, which 
include different truncations to the Apc protein (e.g. Apc
Δ716/+
; Apc
Δ14
); and c) compound 
mutants, which add a mutation to another gene (e.g. mismatch repair genes, Smad1) (33). 
  
6 
Chemically induced models of CRC are advantageous because they are highly 
reproducible, and the approach allows for testing on animals with different genetic 
backgrounds. Importantly, the pattern of cancer development in these models generally 
mimics the multistep process of carcinogenesis observed in human CRC, and most 
tumors develop in the distal colon. A number of chemicals have been show to effectively 
induce carcinogenesis in the colons of rats and/or mice, including the aforementioned 
hydrazine compounds DMH and AOM; some heterocyclic amines, such as 2-amino-1-
methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and 2-amino-33-methylimidazo[4,5-
f]quinolone (IQ); and the alkylnitrosamide compounds methylnitrosourea (MNU) and N-
methyl-N’-nitro-N-nitrosoguanidine (MNNG). AOM is now the most widely used 
chemical carcinogen for modeling sporadic colorectal cancer in rodents. AOM undergoes 
metabolic activation in the liver by the cytochrome P450 enzyme CYP2E1 to form the 
metabolite methylazoxymethane (MAM), which can readily generate a methyldiazonium 
ion that can alkylate DNA at the O
6
 or N
7
 position of guanine (35).  
Disruption of the canonical Wnt/β-catenin signaling pathway is often observed in 
animals initiated with AOM (reviewed in 36, 37). The protein β-catenin aides in cell 
adhesion by associating with either cadherin or catenin to connect the actin cytoskeleton; 
it also acts as a co-transcriptional activator of genes that are under regulation of the Wnt 
signaling pathway. AOM exposure can lead to mutations in codons 31 and 41 of β-
catenin, which prevents its degradation (37). Accumulation of the protein leads to 
transcriptional activation of a number of downstream gene targets that promote cell 
proliferation, such as cyclin D1 (38). AOM exposure also leads to mutations in the proto-
oncogene K-ras, a small G protein that regulates both mitogen-activated protein kinase 
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(MAPK) and phosphatidylinositol 3-kinase (PI3K)/Akt intracellular signaling pathways, 
resulting in dysregulation of cell growth, proliferation, and glucose metabolism (39). One 
of the hallmarks of sporadic and AOM-induced colon cancer is perturbation of the 
transforming growth factor-β (TGF-β) signaling cascade. TGF-β is an important anti-
inflammatory cytokine expressed in colon epithelial cells and serves as a key negative 
regulator of cell proliferation via control of cell growth and apoptotic pathways. The 
tumor suppressor function of TGF-β1 is often lost during tumorigenesis (32). Aberrant 
signaling of the TGF-β1 pathway has been shown in the AOM colon cancer model. 
Disruption of TGF-β1 signaling is characterized by decreased ratios of biologically active 
to inactive TGF-β1 in tumor cells (40), along with transcriptional repression of the TGF-
β1 receptor TβR-II (41).  
Sensitivity to AOM as a chemical carcinogen is highly influenced by the genetic 
background of the animal model used, as well as the route and frequency of 
administration (32, 42, 43). For example, SWR/J and A/J mouse strains are highly 
susceptible to AOM-induced tumors (16 to 36 tumors/mm colon following 8 repeated i.p. 
injections of 10 mg/kg AOM) compared to AKR/J mice, which are very insensitive (<1 
tumor/mm colon) (43). Also, it should be noted that colon carcinogenesis does not appear 
to be influenced by gender, as similar incidence, multiplicity, and size of tumors in males 
and females have been observed previously (42). 
Data from epidemiological studies have shown that CRC risk is strongly linked to 
long-term irritable bowel diseases (IBD), of which the most common types are Crohn’s 
disease and Ulcerative colitis (44-46). The chronic intestinal inflammation that 
characterizes these conditions is now recognized as an important factor in CRC due to its 
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involvement in the disruption of the same oncogenic pathways that are disrupted in CRC 
(47). Both Crohn’s disease and ulcerative colitis are caused by the mutation of several 
genes involved in the maintenance of the intestinal mucosal barrier that protects the 
intestinal wall from bacterial invasion. Dysfunction of this mucosal barrier leads to 
sustained damage of gut epithelial cells. This chronic injury to the gut triggers a 
compensatory immune response characterized by the up-regulation of cell proliferation 
and anti-apoptotic pathways that promote cell survival (48). Various molecules are 
involved in the activation of such pathways, including transcription factors (e.g. NF-κB, 
and STAT3), and various inflammatory cytokines (e.g. IL-6 and TNF- α), which are 
normally secreted during an inflammatory response. The resulting compensatory cell 
regeneration results in increased rates of mitosis that, when chronically active, increase 
DNA mutation rates (48, 49). Not only can this process promote the disruption of 
oncogenic pathways, but it can also provide cancerous cells with a nurturing environment 
due to the increased availability of proliferative and survival signals. This notion is 
supported by an animal study by Tanaka et al. (50), where they showed that a combined 
treatment of AOM with the inflammatory agent dextran sodium sulfate (DSS) 
significantly increased intestinal tumorigenesis in CD-1 mice. The AOM+DSS model 
yields a consistent, reproducible colon cancer outcome that is well defined in terms of 
mouse strain and AOM dosage (51). Moreover, this model recapitulates many of the 
molecular events that occur in spontaneous human colon cancer, such as -catenin 
accumulation and K-ras mutations (37). 
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Dietary factors that promote colorectal carcinogenesis 
 Diet is one of the most influential factors affecting overall cancer incidence, with 
colorectal cancer being one of the most well established examples. The Western diet is 
characterized by high intakes of red and processed meats, fried foods, sweet foods (often 
in the form of soft drinks), and refined grains (5). Conversely, those consuming a western 
type diet typically have low intakes of fruits, vegetables, and fish. Overall, this food 
consumption pattern results in an unbalanced diet that is high in simple sugars, fats, and 
sodium yet low in many essential vitamins, minerals, and fiber (3). Evidence from 
epidemiological and pre-clinical animal studies supports the notion that the Western diet 
is positively associated to a higher risk and incidence of colorectal cancer (3, 5). 
Many elements of a Western diet have been associated with higher rates of CRC. 
In developed countries, excess consumption of red meat has been linked to higher 
incidence of CRC (4, 52-54). Evidence from human case-control and cohort studies 
points to a positive correlation between high red meat consumption and CRC risk. A 6-
year follow-up study using a cohort of 47,949 men from the Health Professionals study 
determined that consumption of beef, pork, and lamb had a strong positive association 
with CRC risk (53). Norat et al. showed that CRC risk was significantly associated with 
pork and lamb consumption in a separate 5-year cohort study of 478,040 men and women 
from Western Europe (54). This association between red meat consumption and CRC risk 
has been attributed, in part, to the presence of N-nitroso compounds, which are known 
alkylating agents (52, 55, 56). Also, red meat naturally contains high levels of heme, 
which generates reactive oxygen species (52, 57). Finally, well-cooked or preserved 
meats can contain high amounts of mutagenic heterocyclic amines (52, 56, 57). 
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Overall, evidence for a role of dietary fat in the etiology of CRC in humans is 
inconsistent. In the previously mentioned Health Professionals Follow-up Study cohort, 
fat from red meat was positively associated with higher CRC risk in men, while no 
association was observed for total fat or non-red meat fat intake (i.e. poultry, dairy, and 
vegetable) (53). Willett and coworkers reported that intakes of animal-derived saturated 
and monounsaturated fats were linked to increased risk of CRC in a prospective study of 
mid-age, healthy women (58). Alternatively, Lin et al. (59) reported that neither total fat 
intake nor intakes of different types of fats or major fatty acids were related to risk of 
CRC in healthy women. Moreover, in a combined analysis of 13 case-control studies 
including 5,287 cases of CRC and 10,470 controls, no evidence of increased risk was 
observed for any dietary fat variable after adjustment for total food energy intake or after 
subgroup analyses by sex, age, or anatomic location of the cancer (60).  
In contrast to human data, the association between dietary fat intake and CRC 
promotion has been repeatedly demonstrated in different rodent models of colorectal 
carcinogenesis. As outlined above, chronic intestinal inflammation is a known risk factor 
for CRC. Researchers have repeatedly shown that intestinal inflammation is enhanced in 
C57BL/6J mice fed with diets with 20% (61), 45% (62), or  60%  kcal from fat (63). In 
chemical carcinogenesis rodent studies, researchers often measure development of 
preneoplastic lesions, termed aberrant crypt foci (ACF), as a biomarker of colorectal 
carcinogenesis. Development of these lesions, as well as fully developed colon tumors, 
has been linked to specific sources of dietary fat. For example, ACF multiplicity was 
significantly higher in the colons of rats fed diets containing 10 or 20% corn oil 
compared to animals consuming diets with 10% or  20% fish oil (38, 64). Evidence from 
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other rat cancer studies suggests that tumor abundance was also greater in animals fed 
corn oil (38, 65) or beef fat (38, 66). On the other hand, consumption of fish or flaxseed 
oil provided protection against colon carcinogenesis in rodents (67-70). Collectively, 
these animal studies provide convincing evidence that the source of dietary fat, rather 
than total fat intake, is the driving factor for modulating colon carcinogenesis in rodents. 
  A number studies have indicated that CRC risk is inversely correlated to the 
consumption of vegetables, fruits, and/or fiber, which are essential components of a 
balanced diet (71). However, current data is not completely consistent, suggesting that 
other interacting factors are likely modulating their effects. For instance, a prospective 
study including 136,089 men and women from the Nurses’ Health Study and Health 
Professionals’ Follow-up Study found no correlation between fruit and vegetable 
consumption, and colon or rectal cancer incidence (72). A meta-analysis of data from 13 
cohort studies analyzed in the Pooling Project of Prospective Studies of Diet and Cancer 
examined the association between dietary fiber intake and CRC risk. The authors 
observed that risk of colorectal cancer in an age-adjusted model was inversely associated 
with dietary fiber intake, although this association was no longer significant after 
adjusting for other risk factors (73). Conversely, a 5-year follow up study of 133,163 U.S. 
men and women examined the association between whole grains, fruit, vegetables, and 
dietary fiber and CRC (74). Although no independent association was observed between 
whole grains, fruit, or fiber and incidence of CRC, very low consumption of vegetables 
and fiber was associated with a 2-fold increase in the risk of colon cancer in men, while 
very low consumption of fruit was associated with a doubling of risk in women. In a 
separate meta-analysis of data from the Pooling Project of Prospective Studies of Diet 
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and Cancer, epidemiologists arrived at a similar conclusion, where the lowest intakes of 
fruits and vegetables (less than 200 g/day) were inversely associated with an elevated risk 
for distal colon cancer risk, but not proximal colon cancer (75). Finally, to examine the 
associations between food patterns and CRC incidence in older Americans, Wirfalt et al. 
(76) performed a cluster analysis in which individuals with similar characteristics were 
aggregated. Male subjects that consumed high amounts of fruits, vegetables, and low fat 
foods were less likely to develop CRC, even when considering other disease risk factors. 
On the other hand, female subjects in this “Vegetable and Fruit” cluster had lower CRC 
incidence, but not independently of other risk factors such as education, smoking, and 
ethnicity.  
Much of the evidence for a role of specific micronutrients in modulation of CRC 
centers on calcium and vitamin D, the latter referring collectively to a group of 
secosteroid molecules that are critical for the uptake of calcium in the intestine. D 
vitamins include cholecalciferol (vitamin D3), which is generally synthesized 
endogenously in response to ultraviolet light, usually in adequate amounts. However, 
some individuals do not obtain sufficient light exposure to maintain adequate levels of 
D3, which is often fortified in staple foods, such as milk, to avoid deficiency (77). 
Overall, evidence from human epidemiological and animal laboratory studies points to 
lower risk of CRC for high intakes of calcium and vitamin D, particularly for senior 
women. Feskanich et al. (78), examined CRC risk in a nested case-control study among 
women participating in the Nurses’ Health Study and determined that women ≥ 60 years 
of age with the plasma levels of 25-hydroxycholecalciferol (25(OH)D), a metabolite of 
D3 and the precursor to the bioactive form 1,25-dihydroxycolecalciferol (1,25(OH)2D), 
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had a much lower risk of CRC compared to subjects in the lowest quintile of 25(OH)D 
levels. Alternatively, this inverse relationship between circulating 25(OH)D and CRC 
risk was not observed in younger women. Lappe et al. (79) examined CRC in healthy, 
post-menopausal women receiving either a calcium supplement (1500 mg), a calcium 
supplement with 1100 IU vitamin D3,or a placebo. Women receiving the dual calcium 
and vitamin D supplement or the calcium supplement alone were more likely to remain 
cancer-free (breast, colon, lung, uterus, and hematopoietic cancers were examined) 
during the 6-year analysis period. Park et al. (80) examined CRC risk as a function of 
dietary calcium and vitamin D intakes, dairy food consumption, and gender and ethnicity 
in the large Multiethnic Cohort Study of more than 215,000 participants. This group 
observed that total calcium intake and consumption of dairy foods were inversely 
correlated with CRC risk in both healthy men and women, and that this relationship for 
calcium was consistent across the ethnic groups examined (African Americans, Native 
Hawaiians, Japanese Americans, Latinos, and Whites). Vitamin D was also found to have 
protective effects in those individuals who do not supplement their diet with additional 
calcium. Evidence from animal studies supports these epidemiological observations. 
Depletion of calcium from the rodent diet increased spontaneous tumor formation while 
vitamin D supplementation inhibited tumorigenesis in C57BL/6J (81) and in Apc
1638N/+
 
mice (82). 
Much of the research on B vitamins and CRC development has focused on 
vitamin B9 (folate), vitamin B6 (pyridoxal phosphate), and vitamin B12 (cobalamin), due 
to their function in the methyl donor pathway and one-carbon metabolism (83, 84). Folate 
is a required for the synthesis, repair, and methylation of DNA, but current data on folate 
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intake and CRC development are inconsistent. In human studies, higher folate intakes are 
generally associated with reduced CRC risk, but data from animal studies suggests that 
the dose and timing of folate intervention differentially modulate carcinogenesis. For 
instance, Sanjoaquin and coworkers (85) performed a meta-analysis that included 7 
cohort and 9 case control studies and found that CRC risk was 25% lower among those in 
the highest category of food-derived folate intake compared with those in the lowest 
category. When analyzing total folate intake (food-derived and supplemented folate), 
only a 5% lower risk was observed. A separate meta-analysis that included 18 case 
control studies and 9 cohort studies from fourteen countries found that CRC incidence 
was decreased 13-18% in the highest quintile of dietary folate intake (86). However, in a 
study where AOM treated rats were given one of 3 diets containing 0, 2, or 8 mg folic 
acid/kg diet, the total number of colonic ACF increased with rising dietary folic acid 
concentration. The total number of colonic ACF was 54% higher in rats fed the 8 mg/kg 
diet than in the rats receiving the 0 mg folic acid/kg diet, suggesting that folic acid 
enhanced colorectal tumorigenesis (87). A separate study using C57BL/6J mice 
determined that colon carcinogenesis was largely unaffected by supplementation with 
dietary folate, although higher intakes of folic acid were linked to a higher proportion of 
relatively large tumors (88). Moreover, neither plasma nor colon folate levels were 
significantly correlated with tumor number (88). 
 The role of vitamin B6 in the etiology or prevention of CRC is also unclear. Je et  
al. (89) performed a meta-analysis of 472 cases of CRC detailed in the Nurses’ Health 
Study, the Health Professionals Follow-up Study, and the Physicians’ Health Study and 
found no association with plasma levels of pyridoxal 5’-phosphate, the active form of B6, 
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and CRC mortality. In a meta-analysis of 8 studies on vitamin B6 intake and 4 studies on 
blood pyridoxal 5’-phosphate levels, Larsson et al. showed that both factors were 
inversely associated with the risk of colorectal cancer (90). Risk of CRC decreased by 
49% for every 100-pmol/mL increase in blood pyridoxal 5’-phosphate level, while high 
vitamin B6 intake was associated with a 20% decreased risk compared to low intake. 
Finally, in CD-1 mice, supplementation with 35 mg of pyridoxine HCl markedly reduced 
CRC incidence compared to a diet depleted in B6 (91). 
 Because of its key role as a cofactor in the one carbon metabolism pathway, many 
researchers have included vitamin B12 in cancer prevention studies. However, like many 
other micronutrients, the role of this particular vitamin in colorectal carcinogenesis 
remains uncertain. In a follow-up study including 226 cases and double matched referents 
from the population-based Northern Sweden Health and Disease Study, Dahlin and 
colleagues found that  plasma vitamin B12 concentrations were inversely associated with 
the risk of rectal cancer, while the association was less clear for colon cancer (92). These 
results are in agreement with an animal study by Choi and colleagues (93), where 30 
Sprague-Dawley rats were fed with either a diet with 50 μg/kg diet of vitamin B12, or a 
diet with no vitamin B12. After 10 wk, the colonic DNA of the deficient rats displayed a 
35% decrease in genomic methylation and a 105% increase in base substitution of uracil, 
which are anomalies that may increase the risk of colorectal carcinogenesis. In other 
studies, researchers often use a combination of vitamin B12 , folate, and vitamin B6, since 
these are all essential components of the one-carbon metabolism pathway, and hence act 
in conjunction. In a randomized, double-blind, placebo-controlled trial, 1,470 female 
health professionals from the Women’s Antioxidant and Folic Acid Cardiovascular Study 
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were randomly assigned to receive either a placebo or a combination pill of folic acid (2.5 
mg), vitamin B6 (50 mg), and vitamin B12 (1 mg). Researchers found no significant 
differences between the treatment and the placebo group (94). These variations and 
inconsistencies in the current data for B vitamins suggest interaction with other dietary 
factors may be modulating their impact on colorectal cancer. 
 Vitamins A (retinol), C (ascorbic acid), and E (tocopherols) are often studied in 
combination because of their known antioxidant activities, but their impact on CRC 
development has not been established conclusively. For instance, a recent study of 816 
CRC cases and 815 controls from the Fukuoka Colorectal Cancer Study showed that 
women with the highest retinol intake had significantly lower risk, while risk for men 
was not significantly different (95). However, carotene, vitamin C, and vitamin E intakes 
were not associated with CRC risk in either men or women. These results contradict the 
findings of a separate study that used data from the North Carolina Colon Cancer Study-
Phase II, which determined that the highest quartiles of  β-carotene intake (another form 
of vitamin A) were inversely associated with reduced risk of distal CRC risk in whites, 
but not in African Americans (96). In this same study, a strong decrease in distal CRC 
was observed in whites in the highest quartile for vitamin C, selenium, and food-derived 
vitamin E intake, but not in the group that included vitamin E supplementation. In an 
xenograft study by Park and colleagues (97), nude immunodeficient mice were injected 
with human CRC cells (HCT-116) and then fed diets containing 2,400 or 200,000 IU 
vitamin A/kg. In this experiment, vitamin A supplementation caused a 4-fold reduction in 
metastatic tumor multiplicity, although tumor size and morphology were unaffected. A 
separate study examined the effects of combined vitamin excess or deficiency in 
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C57Bl/6J mice or Apc
Min/+
 mice (98). Animals were fed either a control diet, a vitamin-
depleted diet (reduced to 33% of the recommended daily allowance [RDA] for mice), or 
a vitamin-supplemented diet (vitamin content increased by 5-fold compared to RDAs for 
mice); the vitamins modified included all of the B vitamins as well as vitamins A, C, D, 
E, and K. Interestingly, these researchers observed that the number and size of colon 
polyps were significantly higher for both experimental diets, suggesting that both 
conditions of vitamin deficiency and excess supplementation were harmful in terms of 
CRC risk. Moreover, this work also underscores the notion that supplementation of diet 
with high levels of vitamins, either individually or in combination, may not be the best 
strategy for CRC prevention.  
 
Modeling the Western diet in animal studies 
As outlined above, many components of a typical Western style diet have been 
shown to modulate cancer risk. Yet, in the vast majority of pre-clinical animal studies to 
investigate mechanisms of carcinogenesis or cancer prevention or to identify new 
strategies for dietary cancer prevention, researchers routinely employ standard formulated 
diets that are generally balanced with respect to macro- and micronutrient levels to 
optimize animal health, such as the American Institute of Nutrition AIN93G diet 
formulation (99). However, these optimally formulated rodent diets are not relevant to 
most human nutrition patterns, especially for at-risk populations that frequently consume 
energy-dense, nutrient-poor foods. Thus, researchers have employed several different 
strategies to model the Western style diet in studies employing rodents to assess impact 
of diet on disease risk and/or development. One such approach is the “cafeteria” diet, in 
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which the animals are allowed free access to standard chow and water, and are 
concurrently offered highly palatable, energy dense, unhealthy human foods ad libitum 
(100). This dietary protocol promotes hyperphagia, rapid weight gain, increased fat pad 
mass, and biomarkers of metabolic syndrome and diabetes, such as glucose intolerance 
and insulin resistance. Some experts argue that the cafeteria diet has limited value as an 
experimental model because of difficulty in replicating the specific dietary conditions 
across experiments or laboratories and because it is poorly defined with respect to 
micronutrient composition (100, 101).  
In a series of studies over the past twenty years, Newmark and colleagues have 
employed a selective approach in modeling the Western diet, wherein specific 
components of the diet are modified to emulate typical U.S. intakes (81, 102, 103). In 
their first study, Newmark et al. developed a “stress” diet, which was quite low in 
calcium and vitamin D3,  and modestly reduced in phosphate compared to the reference 
diet AIN76; also, the stress diet contained 20% fat as corn oil (40% of calories) compared 
to only 5% (12% of calories) in the reference diet (102). A subsequent study extended 
this stress diet to incorporate dietary components necessary for generation of methyl 
donors (folic acid, methionine, choline, and vitamin B12) and determined that this new 
Western diet (NWD) also enhanced spontaneous tumor development in aged C57BL/6J 
mice, an effect that was reversed when calcium and vitamin D were added back to the 
stress diet (81, 103). Although this series of studies has convincingly demonstrated a role 
for dietary calcium and vitamin D3 in modulating spontaneous colon carcinogenesis in 
mice, the scope of the diet remained limited in that it does not consider possible 
contribution of the dietary fat source, carbohydrates or proteins and does not reflect 
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typical human nutrition patterns for other key micronutrients, such as sodium, selenium, 
or vitamins A or E. Commercial Western diets have also been developed for the study of 
obesity; these diets (refered to as diet-induced obesity, or DIO, diets) typically contain 
45% or 60% of energy as fat and differ from the AIN93G diets primarily in their high 
lard and sucrose content (104). Although these high fat diets effectively induce obesity in 
rodents (105), they are extreme in their sugar and fat compositions when compared to a 
typical Western dietary pattern and do not differ substantially from AIN93G diets in 
micronutrient content (104).  
Importantly, none of the approaches described above for modeling typical 
Western nutrition appropriately considered the contribution of suboptimal micronutrient 
intakes in their disease models. To address this resource gap, our research team 
developed the new total Western diet (TWD) for rodents with energy and nutrient 
profiles that emulate a typical Western diet using available U.S. survey data (NHANES). 
The new TWD was formulated using a nutrient density approach, described in detail in a 
recent publication by members of our research group in the Journal of Agricultural and 
Food Sciences (106). Briefly, the amount of each macro- and micronutrient in the 
AIN93G basal diet, a diet routinely used in cancer studies today, was adjusted to match 
50
th
 percentile intakes for Americans as reported in NHANES survey data. These mass 
amounts were then adjusted for caloric intake. Overall, the TWD is not necessarily 
extreme in the level of any given nutrient, but rather reflects the overall dietary pattern of 
the U.S. The TWD has fewer calories from protein and carbohydrate sources, and twice 
that from fat as compared to the AIN93G diet. The new diet contains more saturated and 
monounsaturated fats, less polyunsaturated fat, more complex carbohydrates, and twice 
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the level of simple sugars. The TWD has less calcium, copper, folate, thiamine, and 
vitamins B6, B12, D, and E, but much more sodium. This newly devised diet that better 
represents typical U.S. nutrition is highly useful for studies employing animal models of 
human cancer. For example, results of a preliminary experiment in A/J mice initiated 
with AOM indicate that the TWD markedly enhanced development of preneoplastic ACF 
compared to the reference diet AIN93G (107).  
 
Project objectives and hypotheses 
The objectives of this thesis project were as follows:  1) to investigate the impact 
of dietary macronutrients (protein, carbohydrate, and fat) and micronutrients (vitamins 
and minerals) on biomarkers of metabolic syndrome and 2) to determine the relative 
importance of the macro- and micronutrient composition of the typical Western diet on 
colon cancer risk using a mouse model of inflammation-associated colorectal 
carcinogenesis. This study was designed to test the following working hypotheses: 
1. Mice consuming the TWD will acquire a metabolic syndrome phenotype, 
indicated by increased body weight, glucose intolerance, and insulin resistance, in 
a manner similar to the prototypical commercial high-fat diet (45% fat DIO diet) 
routinely used for diet-induced obesity pre-clinical studies.  
2. TWD consumption will promote colon tumorigenesis in the C57BL/6J strain of 
mouse, which is highly susceptible to diet-induced obesity and metabolic 
syndrome.  
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3. Tumorigenesis in mice fed TWD will be more severe (greater number of and 
larger tumors) compared to mice consuming the standard basal diet AIN93G, 
which was formulated to be optimal for rodent health. 
4. Tumor outcome will be more severe in mice fed TWD (reflecting typical U.S. 
nutrition with respect to both macro- and micronutrients) than in mice consuming 
a diet modified for macronutrient content only. In other words, a typical Western 
micronutrient profile will exacerbate the expected adverse effects of a high-fat, 
high-sugar diet on colon carcinogenesis.  
5. The new TWD will be at least as effective, if not more so, in promoting colon 
carcinogenesis as the DIO diet (high fat only).  
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MATERIALS AND METHODS 
 
 
Chemicals 
AOM was purchased from Sigma-Aldrich (St. Louis, MO; CAS No. 25843-45-2), 
and reagent grade DSS was purchased from MP Biomedicals (Solon, OH; MW=36,000-
50,000 Da). Phosphate buffered saline (PBS) solution was purchased from Caisson Labs 
(Logan, UT), and 10% buffered neutral formalin was purchased from VWR (Houston, 
TX). All other chemicals used were of reagent grade and purchased from general 
laboratory suppliers. 
 
Animals 
The Utah State University Institutional Animal Care and Use Committee 
approved all procedures for the handling and treatment of mice used in this study 
(protocols #2063 and #2114). Animals were housed in the Laboratory Animal Research 
Center (LARC) at Utah State University, which is an AAALAC approved facility. Mice 
were maintained in a pathogen-free vivarium at 18 to 23 °C with a 12:12 hour dark:light 
cycle and humidity between 20 to 50%. Mice were provided Bed-o’Cobs® 1/4 bedding 
(Andersons, Cincinnati, OH). Mice initiated with AOM were housed in HEPA-filtered 
cages on a IVC Air Handling Solutions ventilated housing system (Tecniplast, 
Buguggiate, Italy), while all other mice were housed in wire top cages within a ventilated 
Duo-Flo BioClean Unit (Lab Products, Inc.). Male C57BL/6J mice were obtained from 
Jackson Laboratories (Bar Harbor, ME) at 4 wk of age and acclimated to the vivarium for 
1 wk, during which time mice were provided free access to food and water. 
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Experimental diets 
Experimental test diets were obtained from Harlan-Teklad (Madison, WI). To 
determine the relative impact of dietary macro- and micronutrient composition on 
metabolic health and cancer outcome, we compared 5 different diet formulations as 
outlined in Table 1 and briefly described below:  
1) AIN93G, the standard diet routinely employed in rodent cancer studies 
2) The new total Western diet (TWD), as described in Hintze et al. (106) 
3) A macronutrient-modified diet (MM), which contained the same 
carbohydrate, protein, and lipid content as in the TWD, yet retained the 
vitamin and mineral profile of the reference AIN93G diet 
4) A vitamin- and mineral-modified diet (VMM), which matched the AIN93G 
diet for macronutrient content, yet contained a vitamin and mineral profile 
matching the TWD 
5) A commercial diet-induced obesity diet (DIO) that contained 45% of energy 
as fat (primarily lard) and matched the AIN93G for micronutrient content.  
Diets were obtained as a single lot from the vendor and maintained at 4 °C for the 
duration of the study. Fresh food was provided to mice twice per wk. 
 
Experimental design 
This study was performed in sequential parts, in which the treatment of sham 
mice preceding treatment of AOM+DSS-initiated mice. Sham mice were housed 
individually, whereas mice to be initiated with AOM were housed 5 animals per cage. At 
5 wk of age, mice were randomly assigned to one of the experimental diet groups  
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TABLE 1. Composition of experimental diets 
Nutrient AIN93G TWD VMM MM DIO 
Energy density (kcal/g) 3.8 4.4 3.7 4.4 4.6 
Macronutrient       
Carbohydrates (g/kg diet)      
Corn starch 398 230 398 230 85 
Maltodextrin 132 70 132 70 115 
Sucrose 100 261 100 261 200 
Cellulose 50 30 50 30 58 
kcal (% of total) 60.1% 54.5% 60.1% 54.5% 36.2% 
Proteins (g/kg)      
Casein 200 190 200 190 245 
L-cystine 3 2.8 3 2.8 3.5 
kcal (% of total) 18.8% 15.4% 18.8% 15.4% 19.0% 
Fats (g/kg)      
Soybean oil 70 31.4 70 31.4 30 
Anhydrous milk fat  36.3  36.3  
Olive oil  28.0  28.0  
Lard  28.0  28.0 195 
Beef tallow  24.8  24.8  
Corn oil  16.5  16.5  
Cholesterol  0.4  0.4  
kcal (% of total) 17.2% 34.5% 17.2% 34.5% 44.8% 
Micronutrients      
Minerals (mg/kg)      
Calcium 5000 2011 2011 5000 5000 
Phosphorus 3000 2757 2757 3000 3000 
Sodium 1019 7078 7078 1019 1019 
Potassium 3600 5333 5333 3600 3600 
Magnesium 507 589 589 507 507 
Iron 35 31 31 35 35 
Zinc 30 25 25 30 30 
Copper 6 2.6 2.6 6 6 
Selenium 0.15 0.2 0.2 0.15 0.15 
Vitamins (unit/kg)      
Thiamin (mg) 5 3.5 3.5 5 5 
Riboflavin (mg) 6 4.4 4.4 6 6 
Niacin (mg) 30 50.6 50.6 30 30 
Pyridoxine (mg) 6 3.9 3.9 6 6 
Folate (mg) 2 1.3 1.3 2 2 
Vitamin B12 (μg) 25 11 11 25 25 
Vitamin A (IU) 4000 4300 4300 4000 4000 
Vitamin D (IU) 1000 391 391 1000 1000 
Vitamin E (IU) 75 24.6 24.6 75 75 
Vitamin K (μg) 750 189 189 750 750 
Choline (mg) 1027 648 648 1027 1027 
Note: Abbreviations for experimental diets are as follows:  total Western diet, TWD; vitamin- and 
mineral-modified diet, VMM; macro-modified diet, MM; and diet-induced obesity diet, DIO. 
Composition of the TWD was published previously (106). No data are available in NHANES for 
chloride, manganese, iodine, pantothenic acid, biotin, or ultra-trace minerals. Thus, levels of these 
components in the AIN93G diet were used in the formulation of all experimental diets. 
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described above (N=10 per diet group for sham mice, N=30 per diet group for 
AOM+DSS-initiated mice). For AOM mice, individual animals were tracked using ear 
tags and/or ear punch. Fresh food was provided twice per wk, and food consumption was 
monitored at each change. Individual body weights were recorded once per wk for all 
mice. Body composition of sham mice was determined by MRI scan (EchoMRI-700; 
EchoMRI, Houston, TX) every 4 wk. At 7 wk of age, mice were administered with either 
a subcutaneous injection of 10 mg/kg body weight AOM or sham with an equivalent 
amount of the PBS vehicle. Mice initiated with AOM were also provided 1% DSS via 
their drinking water for 4 wk, then tap water for the remainder of the study. Sham mice 
were provided tap water for the entire study period. After a total of 16 wk on the 
experimental diets, all mice were euthanized by CO2 asphyxiation and necropsied. 
At necropsy of all mice, the liver, kidneys, spleen, and heart were collected, 
weighed, and fixed in 10% buffered neutral formalin. Additionally, to assess fat 
distribution in sham mice, the subcutaneous, gonadal, mesenteric, and retroperitoneal fat 
pads were excised and weighed. Whole blood was obtained from sham mice by cardiac 
venipuncture, and serum was collected by centrifugation (10,000 × g) for 5 min using 
serum separation spin tubes (Sarstedt, Newton, NC). Serum was aliquoted into triplicate 
cryotubes, immediately frozen in liquid nitrogen, and stored at -80°C for analysis of 
plasma hormone concentrations. To assess tumor outcome in AOM+DSS-initiated mice, 
colon tissues were collected from 20 mice per diet group were collected. (Tissue samples 
from the remaining 10 AOM mice per group were preserved for other analyses not 
reported here). Colons were rinsed with PBS, slit open longitudinally from the cecum to 
the anus, placed flat between paper towels, and stored in 70% ethanol solution at 4°C.  
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Fasting glucose and glucose tolerance in sham mice 
Fasting glucose was assessed in sham mice every 4 wk for the duration of the 
study. After a morning fasting period of 6 h, approximately 0.2 μl blood was drawn from 
a 1 mm cut on the tail tip. Glucose was measured using a standard glucose meter and 
glucose strips (Total Diabetes Supply, Boca Raton, FL) in triplicate for each animal. Oral 
glucose tolerance tests were performed on sham mice at wk 7 and 15 of the study. 
Following a morning 6 h fasting period, baseline glucose levels were obtained as 
described above. Then, mice were given a bolus of 10 mg/kg glucose delivered into the 
stomach by gavage needle (22 gauge, 3.81 cm long straight, 2.25 ball diameter). Plasma 
glucose was again measured in triplicate at 0, 15, 30, 60, and 120 min after oral gavage. 
The homeostatic model assessment (HOMA) method was used to assess insulin 
resistance in fasted sham mice using the formula, HOMA = [glucose × insulin]/405, 
where glucose is measured in mass units mg/dL and insulin is expressed as mU/L. 
 
Plasma hormone levels in sham mice 
In order to assess the impact of the experimental diets on biomarkers of 
inflammation and glucose metabolism, 17 plasma circulating hormones were selected for 
analysis: adiponectin, interleukin 2 (IL-2), IL-10, IL-6, monocyte chemotactic protein-1 
(MCP-1), insulin, C-peptide, ghrelin, gastric intestinal peptide (GIP), glucagon-like 
peptide 1, glucagon, leptin, pancreatic polypeptide, peptide YY, resistin, tumor necrosis 
factor alpha (TNFα), and amylin. Serum samples from the sham mice were analyzed 
using a Bio-Plex suspension array system (Bio-Rad Laboratories Inc., Hercules, CA) 
according to the manufacturer’s supplied protocol with no deviation.  
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 Assessment of tumorigenesis in AOM+DSS-initiated mice 
To determine the effect of the experimental diets on colorectal carcinogenesis, 
colon samples were analyzed under a dissecting microscope and tumors were counted. 
The researcher was blinded to the sample identification at the time of assessment. 
Measurements of colon length and tumor volumes were obtained using a pair of 
electronic calipers. Tumors were identified and counted using the following criteria: 1) 
defined, generally round or oval shape, 2) defined, easily distinguishable edges, and 3) 
lighter color with respect to surrounding tissue. Each tumor was measured for length, 
height, and width. Tumor multiplicity was calculated as the number of tumors per mm 
colon for each tumor-bearing animal. Colon volume was estimated using the formula, 
tumor volume = π/6(L×W×D), where L is the length, W is the width, and D is the depth of 
the tumor.  
ACF were identified in using criteria described previously (32, 43). Briefly, ACF 
were characterized as crypts of larger size and often slit-shaped, with increased 
pericryptal area, and thickened layer of epithelial cells which sometimes resulted in 
greater staining around the crypt. Colon tissues were stained in methylene blue for 
approximately 30 sec to facilitate detection of ACF. Colon samples were coded so that 
the corresponding treatment group was not known by the researcher assessing the number 
of foci and the number of crypt cells per foci. 
 
Statistical analyses 
Statistical analyses for food intake, energy intake, body weight, relative organ 
weights, metabolic efficiency, percentage fat and lean mass, fasting glucose, glucose 
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tolerance, plasma hormone concentration, HOMA, tumor multiplicity, tumor volume (log 
transformed), ACF number, and total crypts were performed using mixed models analysis 
of variance (Mixed procedure, SAS 9.3) with the Satterthwaite degrees of freedom 
approximation when needed to account for unequal variances among experimental 
groups. Data for sham or AOM+DSS-initiated mice were analyzed independently, as the 
key experimental question of interest was not the impact of AOM exposure, but rather the 
impact of experimental diet on biomarkers of metabolic health and colon carcinogenesis. 
For analysis of data from AOM+DSS-initiated mice, the parameter cage was included as 
a random factor nested within each diet group to account for cage effects on outcomes. 
Analysis of colon tumor incidence was performed using a quasi-likelihood logistic 
regression (SAS genmod procedure). Finally, all analyses included the Bonferroni 
multiple comparison adjustment to account for multiple testing.   
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RESULTS 
 
 
Food and energy intakes 
Food intakes are reported on a per wk basis (Fig. 1A-B) or for the entire 16 wk 
feeding period (Fig. 1C-D) for individual sham mice or on a per cage basis for 
AOM+DSS-initiated mice. Results of the statistical analyses for food and energy intakes 
by mice fed different experimental diets are presented in Table 2. Over the course of the 
16 wk feeding period, sham and mice fed the AIN93G or VMM diets consumed 
significantly more total food (9 to 16% increase for AIN93G group, 8 to 15% increase for 
VMM group) compared to their counterparts fed the TWD, MM or DIO diets (P < 0.05, 
Fig. 1). Although AOM+DSS-initiated mice were group housed, on a per cage basis, the 
same pattern was evident on a per-cage basis, where mice fed the AIN93G and VMM 
diets generally consumed more total food than mice provided TWD, MM or DIO diets 
(Fig. 1). Also of note was the observation that mice that were group housed consistently 
consumed less food than mice that were individually housed, even though food was 
maintained at sufficient amounts in the AOM+DSS cages throughout the study.  
Energy intakes were calculated using the specific energy density for each 
experimental diet and the recorded food intake values on a per wk basis (Fig. 2A-B) and 
for the entire 16 wk feeding period (Fig. 2C-D). In sham mice, total energy intake for 
animals consuming AIN93G, TWD, or VMM diets was not significantly different (Fig. 
2A,C). On the other hand, energy intakes for mice fed either the MM or DIO diets were 
markedly higher (>5%) compared to all other diet groups (P < 0.05) (Fig. 2A,C; Table 2). 
The pattern of energy intakes across diet groups was slightly different for 
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FIGURE 1. Food consumption in sham or AOM+DSS-initiated mice. Mean food 
intake per wk ± SEM is shown for sham mice (N = 10 individuals) (A) or mice initiated 
with AOM+DSS (N = 4 cages, data normalized by number of mice per cage) (B). Total 
food consumption data for each diet group are represented in box-and-whisker plots (plus 
symbol indicates the treatment group mean and whiskers are 1.5 times the interquartile 
range) for sham (C) or AOM+DSS-initiated mice (D). Different letters indicate that 
treatment groups are significantly different as determined by ANOVA (SAS mixed 
procedure with Satterthwaite approximation); Bonferroni-adjusted P values for multiple 
comparisons among diet groups for sham and AOM+DSS-initiated mice are provided in 
Table 2.  
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FIGURE 2. Energy intake in sham or AOM+DSS-initiated mice. Mean energy intake 
per wk ± SEM is shown for sham mice (N = 10 individuals) (A) or AOM+DSS-initiated 
mice (N = 4 cages, data normalized by number of mice per cage) (B). Total energy intake 
data for each diet group are represented in box-and-whisker plots (plus symbol indicates 
the treatment group mean and whiskers are 1.5 times the interquartile range) for sham (C) 
or AOM+DSS-initiated mice (D). Different letters indicate that treatment groups are 
significantly different as determined by ANOVA (SAS mixed procedure with 
Satterthwaite approximation); Bonferroni-adjusted P values for multiple comparisons 
among diet groups for sham and AOM+DSS-initiated mice are provided in Table 2.  
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TABLE 2. Comparisons among diet groups for food and energy intakes. 
Comparison 
Sham  AOM+DSS-initiated 
 
Food intake Energy intake  Food intake Energy intake 
AIN93G vs. TWD <0.0001 1.0000  <0.0001 <0.0001 
AIN93G vs. VMM 1.0000 0.9568  1.0000 0.0165 
AIN93G vs. MM <0.0001 0.1645  <0.0001 <0.0001 
AIN93G vs. DIO 0.0005 <0.0001  <0.0001 <0.0001 
TWD vs. VMM <0.0001 1.0000  <0.0001 <0.0001 
TWD vs. MM 0.0309 0.0231  1.0000 0.9118 
TWD vs. DIO 0.0062 <0.0001  0.0415 <0.0001 
VMM vs. MM 0.0004 0.0013  <0.0001 <0.0001 
VMM vs. DIO 0.0021 <0.0001  <0.0001 <0.0001 
MM vs. DIO 1.0000 0.0527  1.0000 <0.0001 
Note: Analysis of each indicated parameter was performed by ANOVA (SAS mixed 
procedure) with the Satterthwaite method to approximate degrees of freedom to account 
for apparent unequal variances in parameter measurements among diet groups. For 
AOM+DSS-initiated mice, analyses of food and energy intakes were performed using 
cage data, rather than individual data for AOM+DSS-initiated mice; for all other 
parameters, cage was considered as a random factor nested within the diet treatment 
group. P values of the differences of least squares means are shown for each pair-wise 
comparison among diet groups, and significant differences are shown in bold.  
 
 
AOM+DSS-initiated mice. As in sham mice, energy intake values (normalized to the 
number of mice per cage) were not significantly different between AIN93G and VMM 
groups, and both of these groups had lower energy intakes than mice fed MM or DIO 
diets (Fig. 2D). However, unlike sham mice, energy intake for AOM+DSS-initiated 
animals fed TWD and MM was similar and significantly higher than those fed AIN93G 
(P < 0.0001). These differences in the patterns of food and energy intake among diet 
groups could be attributed to food competition, as AOM+DSS mice were housed in 
groups of 4 to 5 mice during the study. Regardless, as with sham mice, the AOM+DSS-
initiated mice fed the DIO diet consumed significantly more calories (>11%) than all 
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other groups (P<0.0001). Conversely, AOM+DSS-initiated mice fed the VMM 
consumed fewer calories than all other diet groups (P<0.05), reflecting the differences in 
energy density of the diets.  
 
Body weight, organ weights, and metabolic efficiency 
Sham and AOM+DSS-initiated mice gained weight steadily throughout the entire 
study period, although the rate of weight gain (and food consumption) for AOM+DSS-
initiated mice was slightly lower for all diet groups in the week following carcinogen 
injection (Fig. 3A-B). At the conclusion of the study, final body weights for mice 
consuming TWD or VMM diets were not different for mice fed the reference AIN93G 
diet, yet they were significantly lower (P <0.05) than mice fed either the MM or DIO 
diets (Fig. 3C; Tables 3 and 4). A similar pattern was observed for mice initiated with 
AOM (Fig. 3D). Sham or AOM+DSS-initiated mice fed the DIO diet gained about 10 or 
13% more weight, respectively, than their counterparts consuming the AIN93G reference 
diet. However, average final body weights were approximately 19% higher in DIO-fed 
mice (sham and AOM+DSS-initiated) than mice provided the VMM diet, representing 
the largest difference in body weight gain among the experimental diet groups. 
In general, the weights of liver, kidney, and spleen with respect to body weight 
were not markedly affected by dietary treatment, with a few notable exceptions. The 
average relative liver weight for mice that consumed the DIO diet was marginally lower 
(0.47 to 0.58%) compared to all other diet groups (P < 0.05); this pattern was also evident 
in AOM+DSS-initiated mice, though only significant between DIO and AIN93G or 
TWD groups (P = 0.0208 and 0.0002, respectively). However, the absolute liver weights  
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FIGURE 3. Body weight gain in sham or AOM+DSS-initiated mice. Values for body 
weight gain over time ± SEM are shown for sham (N = 10) (A) or AOM+DSS-initiated 
mice (N = 30) (B). Final body weight data for each diet group are represented in box-and-
whisker plots (plus symbol indicates the treatment group mean, and whiskers are 1.5 
times the interquartile range) for sham (C) or AOM+DSS-initiated mice (D). Different 
letters indicate that treatment groups are significantly different as determined by ANOVA 
(SAS mixed procedure with Satterthwaite approximation); Bonferroni-adjusted P values 
for multiple comparisons among diet groups for sham and AOM+DSS-initiated mice are 
provided in Table 4. 
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were not different among diet groups (P > 0.05), suggesting that the difference in relative 
liver weight values was a reflection not of a change in liver health status, but rather the 
body weight of mice consuming the DIO diet. Average relative spleen weight was 
markedly higher (up to 2-fold) in mice consuming TWD or VMM diets compared to 
other diet groups (P ≤ 0.001), although this trend was not observed in sham mice (Tables 
3, 4).  
Metabolic efficiency was calculated for only sham mice, which were singly 
housed (Fig. 4). Animals fed the MM and DIO diets had significantly lower metabolic 
efficiency that TWD and VMM-fed mice, suggesting that they were less efficient and 
converting nutrients into energy. However, neither the MM nor DIO diet groups differed 
significantly from the AIN93-fed animals. Also, metabolic efficiency values for mice 
consuming diets modified in vitamin and mineral content (TWD and VMM diets) were 
not significantly different from mice fed AIN93G. 
 
Body composition and fat distribution  
To determine the impact of the experimental diets on fat accumulation, the body 
composition of sham mice was assessed periodically by MRI (Tables 5,6). In general, the 
rate of lean mass gain among any of the experimental diet groups was similar, and the 
average final lean mass was the same for all groups (Fig. 5A). However, when calculated 
as a percentage of body weight, lean mass at the end of the study was slightly lower in 
mice consuming the MM or DIO diets compared to the VMM diet (P<0.05), yet average 
percentage lean mass was not significantly different for any of the test diet groups 
compared to the reference AIN93G diet group (Fig. 5C). On the other had, a markedly 
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different pattern was observed for effect of diet on fat accumulation over time (Fig. 5B). 
At the end of the study, the average fat mass of mice fed either the MM or DIO diets was 
7 to 12% higher compared to mice fed TWD or VMM (Fig. 5D). A comparison of the 
relative lean and fat mass gain among experimental groups shows that the apparent 
differences in body weight gain in MM and DIO animals was attributed entirely to an 
increase in fat mass.  
 
FIGURE 4. Metabolic efficiency in sham mice. A, Mean metabolic efficiency 
(calculated as weekly energy intake divided by weekly body weight gain) is shown ± 
SEM (N = 10 individuals). B, Values for cumulative metabolic efficiency (total energy 
intake divided by total body weight gain) are represented in box-and-whisker plots (plus 
symbol indicates the treatment group mean and whiskers are 1.5 times the interquartile 
range). Different letters indicate that treatment groups are significantly different as 
determined by ANOVA (SAS mixed procedure with Satterthwaite approximation to 
account for apparent unequal variances); Bonferroni-adjusted P values for multiple 
comparisons among diet groups are provided in Table 5. 
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TABLE 5. Body composition in sham mice. 
Diet Group Week 0 Week 4 Week 8 Week 12 Week 16 
Fat mass      
AIN93G 1.88±1.06 2.53±0.43 3.09±1.31 3.64±0.64 5.34±1.38 
TWD 2.22±0.51 2.58±0.22 2.43±0.35 3.63±0.60 4.52±1.06 
VMM 2.16±0.64 2.59±0.41 2.85±0.70 3.33±1.01 4.14±1.41 
MM 2.72±0.62 3.12±0.49 3.60±0.47 5.38±1.50 7.13±1.92 
DIO 2.14±0.52 2.95±0.75 4.68±1.34 6.16±1.98 8.64±2.88 
Lean mass      
AIN93G 15.32±1.13 17.70±0.79 17.97±1.68 20.63±0.40 19.99±2.11 
TWD 15.33±1.00 16.75±0.74 18.26±0.51 19.75±0.59 19.52±0.93 
VMM 15.03±1.55 16.86±1.59 18.97±1.36 19.36±1.67 19.99±1.35 
MM 14.50±1.56 17.34±0.43 19.04±0.45 19.62±0.86 20.26±1.21 
DIO 15.67±0.80 17.49±0.90 18.97±1.00 20.31±1.81 20.48±1.17 
Note:  Values shown are the average fat or lean mass (g) determined by EchoMRI ± SD for each 
treatment group (N = 10). 
 
TABLE 6. Comparisons among diet groups for  
body composition in sham mice. 
 Lean mass  Fat mass 
Comparison g % of BW  g % of BW 
AIN93G vs. TWD 1.0000 1.0000  1.0000 1.0000 
AIN93G vs. VMM 1.0000 0.6791  1.0000 0.9477 
AIN93G vs. MM 1.0000 1.0000  0.3509 0.4761 
AIN93G vs. DIO 1.0000 0.5086  0.0023 0.0082 
TWD vs. VMM 1.0000 1.0000  1.0000 1.0000 
TWD vs. MM 1.0000 0.2837  0.0282 0.0377 
TWD vs. DIO 1.0000 0.0628  <0.0001 0.0003 
VMM vs. MM 1.0000 0.0204  0.0074 0.0051 
VMM vs. DIO 1.0000 0.0034  <0.0001 <0.0001 
MM vs. DIO 1.0000 1.0000  0.7317 1.0000 
Note: Analysis of each indicated parameter was performed by ANOVA (SAS mixed procedure) 
with the Satterthwaite method to approximate degrees of freedom to account for apparent unequal 
variances in parameter measurements among diet groups. Effects of diet treatment on final lean or 
fat weights (g) and relative weights (%) are were determined separately. P values of the 
differences of least squares means are shown for each pair-wise comparison among diet groups, 
and significant values are shown in bold. 
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FIGURE 5. Body composition of sham mice. Body composition was assessed by MRI 
at wk 0, 4, 8, 12, and 16. The change in lean (A) and fat (B) mass for each diet group over 
time is shown ± SEM (N = 10 individuals). Values for the lean mass (C) and fat mass (D) 
with respect to final body weight (fat mass ÷ body weight × 100) are represented in box-
and-whisker plots (plus symbol indicates the mean for the treatment group, and whiskers 
are 1.5 times the interquartile range). Different letters indicate that treatment groups are 
significantly different as determined by ANOVA (SAS mixed procedure with 
Satterthwaite approximation to account for apparent unequal variances); Bonferroni-
adjusted P values for multiple comparisons among diet groups are provided in Table 8. 
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To determine the impact of experiment diet on fat distribution, we assessed the 
relative mass of subcutaneous, gonadal, mesenteric, and retroperitoneal fat pads with 
respect to final body weight of sham mice at the conclusion of the experiment (Tables 7, 
8). A significant increase in the average percent fat mass was observed for all fat types, in 
animals that consumed either the MM or DIO diets, whereas no significant differences 
were apparent for mice fed AIN93G, TWD or VMM (Fig. 6). This effect of diet was 
most notable for subcutaneous fat, which was twice as abundant in mice fed DIO diet 
compared to the AIN93G, TWD or VMM diets (P < 0.0001). Additionally, a significant 
difference in the ratio of subcutaneous to visceral (gonadal, retroperitoneal, and 
mesenteric) fat was observed when comparing mice fed AIN93G (0.66 ratio) to those that 
consumed the DIO diet (0.91 ratio) (P <0.01), whereas this ratio was not different among 
mice fed either the TWD, VMM or MM diets. 
 
Fasting glucose and glucose tolerance in sham mice 
To assess the impact of experimental diets on biomarkers of metabolic syndrome, 
we measured fasting glucose and oral glucose tolerance periodically throughout the study 
in a subset of 6 mice randomly selected from each treatment group. At the start of the 
study, average fasting glucose levels were similar for all treatment groups (Fig. 7), and 
this trend among treatment groups was fairly consistent throughout the experiment (Table 
9). At the conclusion of the study, average fasting glucose levels were not significantly 
different compared between the reference AIN93G diet and the other experimental diet 
groups (Fig. 7C). However, fasting glucose was elevated in DIO-fed mice compared to 
those that consumed the VMM diet (P = 0.0043).  
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TABLE 8. Comparisons among diet groups for  
fat distribution in sham mice. 
Comparison 
Subcutaneous 
(% of BW) 
Gonadal 
(% of BW) 
Mesenteric 
(% of BW) 
Retroperitoneal 
(% of BW) 
AIN93G vs. TWD 1.0000 1.0000 1.0000 1.0000 
AIN93G vs. VMM 1.0000 1.0000 1.0000 0.6698 
AIN93G vs. MM 0.0079 0.0107 0.0011 0.0174 
AIN93G vs. DIO <0.0001 0.0007 <0.0001 <0.0001 
TWD vs. VMM 1.0000 1.0000 1.0000 1.0000 
TWD vs. MM 0.0389 0.0017 0.0033 0.0366 
TWD vs. DIO <0.0001 <0.0001 <0.0001 <0.0001 
VMM vs. MM 0.0412 0.0001 0.0002 1.0000 
VMM vs. DIO <0.0001 <0.0001 <0.0001 0.0023 
MM vs. DIO 0.0087 1.0000 0.1211 0.1265 
Note: Analysis of each indicated parameter was performed by ANOVA (SAS mixed procedure) 
with the Satterthwaite method to approximate degrees of freedom to account for apparent unequal 
variances in parameter measurements among diet groups. P values of the differences of least 
squares means are shown for each pair-wise comparison among diet groups, and significant 
values are shown in bold.  
 
 
Glucose tolerance was assessed by calculating the area under the curve (AUC) for 
oral glucose tolerance tests performed at wk 7 and 15 of the study (Fig. 8). Values for 
AUC for the DIO group were significantly higher (by about 50%) than mice fed the 
AIN93G and VMM diets at both time points assessed (Fig. 8; Table 9), but other dietary 
treatment groups did not alter glucose tolerance in comparison to the reference AIN93G 
diet.  
 
Plasma hormone levels in sham mice 
At the conclusion of the study, levels of a variety of hormones critical to 
regulation of food intake, inflammation, and development of metabolic syndrome were 
measured in blood samples collected from sham mice. Seven in the multiplex assay were 
reliably detected in all samples, including adiponectin, resistin, leptin, insulin, GIP, 
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FIGURE 6. Fat distribution in sham mice. Values for the percentage subcutaneous (A), 
gonadal (B), mesenteric (C), and retroperitoneal fat (D) and the ratio of subcutaneous fat 
to visceral fat (including gonadal, mesenteric and retroperitoneal) (E) are represented in 
box-and-whisker plots (plus symbol indicates the mean for the treatment group, and 
whiskers are 1.5 times the interquartile range). Different letters indicate that treatment 
groups are significantly different as determined by ANOVA (SAS mixed procedure with 
Satterthwaite approximation to account for apparent unequal variances); Bonferroni-
adjusted P values for multiple comparisons among diet groups are provided in Table 7.  
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FIGURE 7. Fasting glucose levels in sham mice. Fasting glucose was determined at the 
start of the study, then again at wk 4, 8, 12, and 16 (A). The change in fasting glucose for 
each diet group over time is shown ± SEM (N = 6). Values for fasting glucose at wk 0 (B) 
and at wk 16 (C) are represented in box-and-whisker plots (plus symbol indicates the 
mean for the treatment group, and whiskers are 1.5 times the interquartile range). 
Different letters indicate that treatment groups are significantly different as determined 
by ANOVA (SAS mixed procedure with Satterthwaite approximation to account for 
apparent unequal variances); Bonferroni-adjusted P values for multiple comparisons 
among diet groups for each time point are provided in Table 9. 
 
  
     
46 
4
6
 
TABLE 9. Comparisons among diet groups for fasting glucose levels  
and oral glucose tolerance in sham mice.  
 Fasting glucose  oGTT 
Comparison Wk 0 Wk 4 Wk 8 Wk 12 Wk 16  Wk 7 Wk 15 
AIN93G vs. TWD 1.0000 1.0000 1.0000 1.0000 1.0000  1.0000 1.0000 
AIN93G vs. VMM 1.0000 1.0000 1.0000 1.0000 1.0000  1.0000 1.0000 
AIN93G vs. MM 1.0000 1.0000 1.0000 1.0000 1.0000  1.0000 1.0000 
AIN93G vs. DIO 0.0477 0.0395 1.0000 1.0000 0.3022  0.0477 0.0395 
TWD vs. VMM 1.0000 1.0000 1.0000 1.0000 0.3628  1.0000 1.0000 
TWD vs. MM 1.0000 1.0000 1.0000 1.0000 1.0000  1.0000 1.0000 
TWD vs. DIO 0.1054 0.1202 1.0000 1.0000 1.0000  0.1054 0.1202 
VMM vs. MM 1.0000 1.0000 1.0000 1.0000 0.1589  1.0000 1.0000 
VMM vs. DIO 0.0277 0.0137 1.0000 0.7892 0.0043  0.0277 0.0137 
MM vs. DIO 0.1403 0.2396 1.0000 1.0000 1.0000  0.1403 0.2396 
Note: Analysis of each indicated parameter was performed by ANOVA (SAS mixed procedure) 
with the Satterthwaite method to approximate degrees of freedom to account for apparent unequal 
variances in parameter measurements among diet groups. P values of the differences of least 
squares means are shown for each pair-wise comparison among diet groups, and significant 
values are shown in bold. 
 
C-peptide, and IL-6, while the levels of the other 10 hormones were below the detection 
limit of the assay. For the most part, the experimental diets did not significantly impact 
circulating hormone levels (Fig. 9). Two notable exceptions included leptin, which was 
elevated in mice fed DIO approximately 2-fold compared to mice provided the AIN93G, 
VMM or TWD diets (P < 0.01); plasma leptin levels were also elevated in mice fed the 
MM diet compared to mice consuming the AIN93G, TWD, and VMM diets (Fig. 9C). 
Lastly, plasma levels of GIP were significantly higher in mice consuming TWD 
compared to the VMM-fed animals, although neither group were significantly different 
from the reference AIN93G diet or the DIO diet group (Fig. 9D). Finally, the HOMA 
method was used to calculate insulin resistance, which was significantly higher in mice 
fed the DIO diet compared to those fed TWD (P < 0.01), although neither group was 
significantly different from the AIN93G, VMM or MM groups (Fig. 10) 
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FIGURE 8. Oral glucose tolerance in sham mice. Results of oral glucose tolerance 
tests at wk 7 (A) and wk 15 (B) are shown. Symbols represent mean glucose levels ± 
SEM (N = 6). Glucose tolerance was assessed by calculating the area under the curve 
(AUC) with baseline set at 100 mg/dL. Calculated AUC values for oGTT at wk 7 (C) and 
at wk 15 (D) are represented in box-and-whisker plots (plus symbol indicates the mean 
for the treatment group, and whiskers are 1.5 times the interquartile range). Different 
letters indicate that treatment groups are significantly different as determined by ANOVA 
(SAS mixed procedure with Satterthwaite approximation to account for apparent unequal 
variances); Bonferroni-adjusted P values for multiple comparisons among diet groups for 
each time point are provided in Table 5. 
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FIGURE 9. Plasma hormone levels in sham mice. Mean plasma concentrations of 
adiponectin (A), resistin (B), leptin (C), gastric inhibitory peptide (GIP) (D), insulin (E), 
c-peptide (F) and IL-6 (G) are shown ± SEM (N = 6 to 10). Different letters indicate that 
treatment groups are significantly different as determined by ANOVA (SAS mixed 
procedure with the Bonferroni adjustment for multiple comparisons).  
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FIGURE 10. Insulin resistance by the homeostatic model assessment (HOMA) 
method. HOMA was calculated using matched values for fasting glucose and insulin at 
16 wk as described in Methods. Average HOMA values are shown ± SEM (N = 6). 
Different letters indicate that treatment groups are significantly different as determined 
by ANOVA (SAS mixed procedure with the Bonferroni adjustment for multiple 
comparisons).  
 
Impact of experimental diets on colon tumorigenesis 
The most critical objective of this study was to assess the impact of experimental 
diet on colorectal carcinogenesis. At the end of the feeding trial, the number of 
preneoplastic lesions and the incidence, abundance and size of colon tumors were 
determined in a subset of mice initiated with AOM+DSS (N = 20) (Tables 10, 11). 
Values for all of these parameters are expressed on a colon length basis, as colon tissues 
with high tumor burden tend to be shorter in length and thus have less surface area. As 
expected with this initiation protocol, nearly all animals fed the reference AIN93G diet 
acquired colon cancer. However, tumors were detected in only 80% of the mice fed DIO  
diet, which was marginally significantly different (P=0.0479) from the 100% cancer 
incidence observed in mice fed TWD, VMM or MM diets (Table 10).  
On the other hand, striking significant effects of experimental diet on tumor 
multiplicity and size were observed. Mice provided either the TWD or VMM diets had 
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nearly twice as many tumors as their AIN93-fed counterparts (P< 0.01), and about 3-
times the number of tumors as animals provided the MM or DIO diets (P <0.0001) (Fig. 
11A). However, tumor multiplicity was not significantly different in animals fed the MM 
or DIO diets compared to the AIN93G group.  
A very similar pattern for tumor volume was also evident, as the average tumor 
size in mice provided TWD or VMM diets was about 3.6- to 2.5-fold higher than in mice 
fed AIN93G diet (P <0.01) (Fig. 11B). An even more pronounced increase in tumor 
volume was observed, a nearly 10-fold difference, when comparing the TWD and VMM 
groups to mice fed MM or DIO diets (P < 0.0001). Moreover, average tumor volumes in 
mice fed TWD and VMM were significantly greater than tumor volume for the reference 
AIN93G group (P = 0.0009 and 0.022, respectively).  
To determine whether mice fed MM or DIO diets acquired a large number of 
preneoplastic lesions that failed to progress to tumors, we counted the average number of 
aberrant crypts and the number of ACF (Fig. 11C-D) (Table 10). No significant 
differences among diet groups were observed (Table 11), although the low variance 
evident in the TWD and VMM likely reflects that many of the preneoplastic in these diet 
groups progressed to form colon tumors. 
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TABLE 11. Comparisons among diet groups for colon tumorigenesis in mice 
initiated with AOM+DSS. 
 Tumor outcome  Aberrant crypts 
Comparison Incidence Multiplicity Volume  Number foci Total crypts 
AIN93G vs. TWD 1.0000 0.0031 <0.0001  0.6413 1.0000 
AIN93G vs. VMM 1.0000 <0.0001 0.0027  1.0000 1.0000 
AIN93G vs. MM 1.0000 1.0000 0.0009  1.0000 1.0000 
AIN93G vs. DIO 0.2982 0.1177 0.0220  1.0000 1.0000 
TWD vs. VMM 1.0000 1.0000 1.0000  1.0000 1.0000 
TWD vs. MM 1.0000 <0.0001 <0.0001  1.0000 1.0000 
TWD vs. DIO 0.0479 <0.0001 <0.0001  0.2880 0.1877 
VMM vs. MM 1.0000 <0.0001 <0.0001  1.0000 1.0000 
VMM vs. DIO 0.0479 <0.0001 <0.0001  1.0000 0.6011 
MM vs. DIO 0.0479 1.0000 1.0000  1.0000 1.0000 
Note: Analysis of tumor incidence was performed using a quasi-likelihood logistic regression 
(SAS genmod procedure), while tumor multiplicity, tumor volume (log-transformed), number of 
aberrant crypt foci and number of crypts per foci were analyzed using a mixed model ANOVA 
(SAS mixed procedure) with the Satterthwaite method to approximate degrees of freedom to 
account for apparent unequal variances in parameter measurements among diet groups. P values 
of the differences of least squares means are shown for each pair-wise comparison among diet 
groups, and significant values are shown in bold.  
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FIGURE 11. Colon tumorigenesis in mice initiated with AOM+DSS. Tumor 
multiplicity (number of tumors for tumor-bearing animals normalized by the colon 
length) (A), tumor volume (calculated as V = π/6 (L×W×D) where L is length, W is width, 
and D is depth) (B), aberrant crypt foci (number of foci for mice with foci) (C), and total 
crypts (total number of aberrant crypts for animals with foci) (D) are represented in box-
and-whisker plots (plus symbol indicates the mean for the treatment group, and whiskers 
are 1.5 times the interquartile range). Different letters indicate that treatment groups are 
significantly different as determined by ANOVA (SAS mixed procedure with 
Satterthwaite approximation to account for apparent unequal variances); Bonferroni-
adjusted P values for multiple comparisons among diet groups are provided in Table 10. 
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DISCUSSION 
 
 
We report for the first time that a newly devised diet that recapitulates U.S. 
nutrition patterns with respect to macro- and micronutrient content markedly enhanced 
colorectal carcinogenesis in a mouse model of inflammation-associated colon cancer 
compared to a basal diet optimized for rodent health. Moreover, we determined that the 
micronutrient components of the TWD were primarily responsible for increased cancer 
susceptibility in these mice. This study is the second from our group to show that this diet 
functions to promote colon cancer in mice. Previously, we showed that A/J mice initiated 
with AOM and fed TWD for 16 wk developed significantly more ACF and total crypt 
cells than mice fed the AIN93G diet (107). Interestingly, green tea supplementation 
(0.2% Polyphenon E) markedly reduced the accumulation of aberrant crypts in animals 
fed the TWD, but did not alter colon carcinogenesis in animals consuming AIN93G. 
These observations pointed to a complex, yet critical interaction between basal diet and 
the activity of a well-established anticancer agent.  
In an effort to understand better the impact of this westernized diet on cancer 
susceptibility, we sought to determine the relative impacts of the macro- and 
micronutrient components of the TWD on colon cancer as well as on biomarkers of 
metabolic syndrome and obesity in comparison to the commercial 45% fat DIO diet. As 
expected, mice consuming the DIO diet acquired an obesity/metabolic syndrome 
phenotype typified by increased food energy intake, greater rate of body weight gain, 
increased proportion of body composition as fat mass, higher fasting glucose, impaired 
glucose tolerance, and higher circulating levels of leptin. However, the TWD did not 
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significantly alter any of these classic biomarkers of metabolic health, a somewhat 
surprising observation considering that this diet contains substantially more fat than the 
AIN93G diet (35 compared to 17 percent of total kcal, respectively). Furthermore, our 
observations also suggest that the DIO diet does not enhance colon cancer in the 
AOM+DSS model, a finding somewhat contrary to prior observations for ACF in rats 
(66, 108). While this later finding was admittedly unexpected, it points to the critical 
need to employ a diet model that represents typical human nutrition. Had the experiment 
design included only DIO diet as the model obesogenic Western diet, we could have 
easily (and erroneously) concluded that colorectal cancer risk in mice was unaffected by 
the Western nutrition pattern. Moreover, we would have missed the more remarkable 
discovery that inappropriate micronutrient consumption strongly increased colon 
tumorigenesis in this mouse model, as evidenced by highly similar results for the TWD 
and the VMM diets, both of which had vitamin and mineral content that reflects typical 
American nutrition. Modification of macronutrient content alone (i.e., DIO and MM 
diets) did not increase colorectal carcinogenesis, an observation that also points to a 
critical role for micronutrients in promoting colorectal carcinogenesis in this pre-clinical 
mouse model.  
Numerous studies have shown that consumption of a high fat diet promotes a gain 
in relative fat mass in a dose-dependent manner (109). The higher adiposity observed in 
animals fed either the MM or DIO diets reflected the relatively high fat content of these 
diets (34 and 45%, respectively). However, new evidence points to a role in the source of 
dietary fat for influencing fat deposition and subsequent impacts on parameters of 
metabolic health. Catta-Preta et al. (110) reported that C57BL/6J mice fed a diet 
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containing 60% fat from lard or olive oil had higher levels of plasma insulin, resistin, and 
leptin, compared to mice fed diets with 60% sunflower oil or canola oil. Moreover, the 
ratio of subcutaneous to visceral fat was at least 40% smaller in animals fed the lard or 
olive oil diets compared to animals provided diets containing other lipid sources. The fat 
source for the DIO diet is primarily lard, whereas the fat content of the AIN93G and 
VMM diets is exclusively soybean oil. The MM and TWD diets incorporate a variety of 
fat sources relevant to typical Western nutrition, including soybean oil, milk fat, lard, 
olive oil, beef tallow, and corn oil. Interestingly, in this study, the ratio of subcutaneous 
to visceral fat was significantly higher in mice fed DIO compared to the reference 
AIN93G diet. However, we did not detect a difference in the fat type ratio between the 
DIO and MM diets, although these diets are not directly comparable due to their 
difference in total fat concentration. In another study by Huang et al. (111), higher levels 
of leptin and the pro-inflammatory hormones resistin, MCP-1 and CD192 were observed 
in C57BL/6J mice fed a 38% safflower oil diet rich in polyunsaturated fatty acids 
compared to isocaloric diets containing lard and milk fat. Our analysis of plasma 
hormones also included adiponectin, resistin, insulin, GIP, C-peptide, and IL-6. These 
hormones and cytokines, which are involved in energy balance and inflammation, are 
important biomarkers for systemic inflammation and colorectal cancer (19, 112). 
Unfortunately, the results of the hormone analysis for our study were limited because of 
the high variability in measurements among mice or because plasma concentrations of 
some hormones were below the assay limit of detection. However, blood plasma levels of 
leptin were closely correlated with body composition, as expected for this fat-derived 
hormone (113).  
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The consumption of a high fat diet is strongly linked to high rates of obesity due 
to increased energy intake, as opposed to greater food mass consumption (see review by 
109). Observations from our study concur with this model, in that mice fed the DIO diet 
had significantly greater energy intake than their AIN93G-fed counterparts, yet lower 
food mass consumption. Importantly, these animals did not completely adjust their food 
consumption so that their energy intake was on par with animals consuming the reference 
diet. Moreover, this pattern was consistent throughout the study, indicating that DIO-fed 
mice did not adequately adapt over time to the high fat content of their diet. On the other 
hand, sham mice fed TWD consumed the least mass of food of any diet group, and this 
decrease was sufficient to normalize their total energy intake to that of the AIN93G-fed 
mice. As a consequence, mice fed the TWD did not gain excess weight nor develop 
biomarkers of obesity-induced metabolic syndrome. This difference in energy intake 
cannot be attributed solely to the modest 10% difference in fat content of these 2 diets, as 
sham mice fed the MM diet (matched to TWD for all macronutrients) had significantly 
greater food and energy intake compared to TWD-fed animals. That these observations 
were not entirely consistent for AOM+DSS-initiated mice could be attributed to 
competition among cage-mates or other behavior effects present in group-housed male 
mice.  
The results of this study indicate that micronutrients contribute to colorectal 
carcinogenesis to a greater extent than do macronutrients in a mouse model of 
inflammation-associated colon cancer. For many endpoints evaluated, we observed that 
the data segregated into groups based on similarity in response:  MM and DIO diets (with 
high fat the common feature); TWD and VMM diets (with modified vitamins and 
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minerals the common feature) and then the reference diet AIN93G. For endpoints 
associated with obesity and metabolic syndrome, significant effects were often observed 
for the MM and DIO diets, but not the others. The opposite pattern was evident for colon 
cancer outcome, with significant effects of diet apparent only for mice fed TWD or MM 
diets. Evidently, increased tumorigenesis in mice fed either of these diets was not linked 
to higher rates of obesity or metabolic syndrome. Because the TWD models the typical 
U.S. diet with respect to nearly all major micro- and macronutrient components, it is not 
possible to confidently single out one (or a few) constituents responsible for its tumor 
promoting effect. Nevertheless, our strategy is an important advance on prior studies that 
investigated the impact of only one or a select few components of the Western diet on 
colon cancer. 
The nutrient density approach was previously employed by Newmark et al. (102) 
to construct a Western-type diet containing the levels of fat, phosphorous, calcium, and 
vitamin D observed in average American diets. Compared to the AIN76A diet, their 
Western diet contained higher levels of fat and phosphorous, and lower levels of calcium 
and vitamin D. C57BL/6J mice fed their Western diet promoted spontaneous hyper-
proliferation and hyperplasia in colonic epithelium. In a subsequent study, this further 
modified this experimental diet by reducing levels of components critical for methyl 
donor generation, including folic acid, methionine, and vitamin B12 (103). Consumption 
of this modified western diet led to higher rates of spontaneous colon adenoma and 
carcinoma development in normal mouse colon. Other number of other rodent studies 
using the AOM model of CRC point to a role for high fat diet in enhancing colorectal 
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carcinogenesis, even though the fat composition in these experiments varied widely (38, 
63, 97, 114, 115).  
Alternatively, the importance of various dietary micronutrients on CRC 
development has also been shown in a number of animal and human studies. The TWD 
contains low amounts of several essential micronutrients when compared to both the DIO 
diet and RDA values for humans (106). On an energy density basis, amounts of vitamins 
B6, B12, and folate are about 33 to 50% of the TWD compared to the AIN93G control 
diet, while calcium and vitamin D levels are approximately 60% lower.  
As outlined in the introduction, evidence from human epidemiological studies and 
experiments in animal models points to a role for both calcium and vitamin D in 
modulation of CRC (116-118). Calcium functions to regulate cellular signaling, cell 
proliferation and cell growth, while vitamin D is critical for adequate uptake of calcium 
in the small intestine. A 24-wk study on Apc
1638N/+ 
mice, which have a truncation on 
codon 1638 of the tumor suppressor Apc gene, found that feeding a modified AIN76A 
diet with half the content of vitamin D and 90% less calcium resulted in the formation of 
colonic adenomas and a carcinomas, and enhanced expression of cyclin D1 and anti-
apoptotic protein Bcl-2, which are commonly overexpressed in colorectal cancer (82). In 
a different study using this same diet fed to C57BL/6J mice over a period of 3 and 6 
months, researchers identified important transcriptome changes associated with induction 
of the oxidative stress response pathway (119). Moreover, calcium and vitamin D were 
determined to be important regulators of bile acid synthesis and excretion. Vitamin D has 
been shown to be involved in the detoxification of bile acids through the regulation of 
fibroblast growth factor 15 (120) and the vitamin D receptor (121) in the intestine, while 
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calcium has been shown to increase fecal fatty acid excretion (122, 123). Bile acids 
contribute to colorectal carcinogenesis by increasing cellular oxidative stress, and they 
have been associated with the promotion of cell populations resistant to their apoptotic 
effects (124). Bile acids are the main pathway for cholesterol catabolism in mammals, 
and hence they are generally found in high levels in individuals that consume a high-fat 
diet (125). Thus, the combined impact of excess fat with low calcium and vitamin D 
content in the TWD could explain the promoting effect of this diet on colon 
tumorigenesis observed in this study. 
Choline, folate, and vitamins B6 and B12 are essential in cellular biosynthetic 
pathways due to their roles as donors of methyl groups for one carbon-metabolism (84). 
These micronutrients are present in the AIN93G diet at substantially greater levels than 
the RDA value for humans, when compared on an energy density basis (106). Moreover, 
the TWD contains substantially lower levels of these micronutrients than are present in 
the AIN93G diet. A case-control study of subjects from the Multiethnic Cohort study 
found that people in the highest quartile for pyridoxal-5’-phosphate intake (active form of 
B6) had a 48% reduction in CRC risk (126). A meta-analysis that included 7 cohort-
studies and 9 case-control studies found a 25% lower risk of CRC among those in the 
highest category of dietary folate intake compared with those in the lowest category, 
while only a 5% lower risk was observed for total folate intake (including supplements) 
(85). An animal study using male Sprague-Dawley rats fed with either a diet with 50 
μg/kg diet of vitamin B12 or a diet with no vitamin B12 found that, after 10 wk of feeding, 
rats fed the deficient diet displayed a 35 percent decrease in genomic methylation and a 
105 percent increase in base substitution of uracil. Although some studies have found 
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weak or no association between CRC risk or development and dietary B-vitamins (87, 89, 
127), the supporting evidence points to a complex interaction between other nutrients in 
the diet. Also, the low levels of B-vitamins in the TWD could explain the promoting 
effect on tumorigenesis observed in animals fed this diet. 
In conclusion, evidence from this work supports the idea that a rodent diet more 
representative of the diet consumed by the majority of Americans is necessary to 
appropriately evaluate colon cancer risk and to develop specific and effective prevention 
strategies. Diets that modeled Western nutrition with respect to macronutrient content 
only yielded a greatly different disease phenotype than did a diet that also took into 
account suboptimal micronutrient consumption. The health consequences of chronic low 
intakes of multiple micronutrients are not well understood and should be studied in the 
context of modern dietary patterns. To extend upon this work, our research group plans to 
investigate the impact of TWD using the well-established APC
Min/+
 genetic mouse model 
of gastrointestinal carcinogenesis. Also, our group will continue to investigate molecular 
markers of colorectal carcinogenesis in colon mucosa obtained from sham and 
AOM+DSS-initiated mice from this project using global gene expression microarrays 
and immunohistochemistry. Finally, given the profound impact of the TWD on colon 
carcinogenesis and the mounting evidence for perinatal or transgenerational impacts of 
diet on cancer risk (128-135), we plan to investigate the impact of TWD provided via the 
maternal diet on risk of cancer to offspring.  
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